Bernelin H, et al. - Researchers assessed whether neprilysin (NEP) plasma levels following reperfusion might be a surrogate for infarct size (IS) or predict adverse outcomes in patients with acute ST-segment elevation myocardial infarction (STEMI). They measured NEP levels in a prospective cohort of 203 patients with STEMI referred for primary percutaneous coronary intervention. The investigators found that NEP serum levels were widely distributed and did not change significantly in the first hours and 1-month period following reperfusion in these patients. Overall, they did not observe any significant relationship with markers of IS, inflammation, and 1-year adverse outcomes.